Compare EZPW & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EZPW | ZYME |
|---|---|---|
| Founded | 1989 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 1996 | 2022 |
| Metric | EZPW | ZYME |
|---|---|---|
| Price | $28.37 | $29.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 14 |
| Target Price | $41.00 | ★ $42.43 |
| AVG Volume (30 Days) | 747.5K | ★ 1.2M |
| Earning Date | 11-11-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 29.09 | ★ 33.33 |
| EPS | ★ 1.65 | 1.08 |
| Revenue | ★ $747,954,000.00 | $105,965,000.00 |
| Revenue This Year | $8.21 | $195.79 |
| Revenue Next Year | $7.16 | $14.68 |
| P/E Ratio | ★ $17.19 | $27.01 |
| Revenue Growth | 2.39 | ★ 38.87 |
| 52 Week Low | $16.50 | $18.20 |
| 52 Week High | $37.13 | $31.97 |
| Indicator | EZPW | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 40.48 | 53.04 |
| Support Level | $27.73 | $22.23 |
| Resistance Level | $31.62 | $29.75 |
| Average True Range (ATR) | 1.18 | 1.35 |
| MACD | -0.07 | 0.13 |
| Stochastic Oscillator | 24.53 | 39.23 |
EZCORP Inc is a United States-based company engaged in offering pawn loans in the United States and Mexico. It also offers short-term unsecured loans and other consumer financial products, and buys and sells second-hand goods. The operating segments of the company are U.S. Pawn, Latin America Pawn, and Other Investments. The U.S. Pawn segment includes all pawn activities in the United States. The Latin America Pawn segment includes all pawn activities in Mexico and other parts of Latin America. The company generates revenue from merchandise sales, jewelry scrapping sales, and pawn service charges, of which key revenue is derived from the merchandise sales, which are mainly collateral forfeited from pawn lending operations and used merchandise purchased from the customers.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.